Blog

Dec 17, 2024, 06:38

Matthias Guckenberger: What modern radiotherapy can achieve for elderly breast cancer patients

Matthias Guckenberger, Radiation Oncologist at University Hospital Zurich, shared on X:

“Remember the misleading press reports about ‘brutal’ radiation oncology after PROSPECT ?

This is what modern radiotherapy can achieve for elderly breast cancer patients!
– ‘Endocrine Tx was associated with a greater reduction in HRQOL compared with RT at 24 months’
– oncological data awaited.”

Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial

Authors: Icro Meattini, Maria Carmen De Santis, Luca Visani, Marta Scorsetti, Alessandra Fozza, Bruno Meduri, Fiorenza De Rose, Elisabetta Bonzano, Agnese Prisco, Valeria Masiello, Eliana La Rocca, Ruggero Spoto, Carlotta Becherini, Gladys Blandino, Luca Moscetti, Riccardo Ray Colciago, Riccardo A Audisio, Etienne Brain, Saverio Caini, Marije Hamaker, Orit Kaidar-Person, Matteo Lambertini, Livia Marrazzo, Calogero Saieva, Tanja Spanic, Vratislav Strnad, Sally Wheelwright, Philip M P Poortmans, Lorenzo Livi, on behalf of the EUROPA Trial Investigators

Matthias Guckenberger

Agnese Prisco Alessandra Fozza Bruno Meduri Calogero Saieva Carlotta Becherini Eliana La Rocca Elisabetta Bonzano Etienne Brain EUROPA Trial Investigators Fiorenza De Rose Gladys Blandino Icro Meattini Livia Marrazzo Lorenzo Livi Luca Moscetti Luca Visani Maria Carmen De Santis Marije Hamaker Marta Scorsetti Matteo Lambertini Matthias Guckenberger Orit Kaidar-Person Philip M P Poortmans Riccardo A Audisio Riccardo Ray Colciago Ruggero Spoto Sally Wheelwright Saverio Caini Tanja Spanic Valeria Masiello Vratislav Strnad

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage